Cardiovascular outcomes Semaglutide (SELECT) in overweight/obesity without diabetes: 20% reduction in 3-point MACE (Pfeffer et al., 2023)
They also make your body more resistant to insulin and can increase inflammation, both of which get in the way of how well GLP-1 works
As demand for more sophisticated treatment options for metabolic disorders grows, healthcare providers are increasingly under pressure in terms of costs
Acknowledgements We thank Diana van Tuijl, Inge Wolterink-Donselaar, Jos Brits, Harrie van der Eerden, and Henk Spierenburg for their practical assistance
References 1 AbbasT.FaivreE.HlscherC
Key limitation: compendia support does not override Part Ds statutory exclusionsso it doesnt turn an excluded weight-loss use into a covered use